Insulet’s modeled fair value per share has been tweaked from US$354.40 to US$354.12, a very small adjustment that still caught investors’ attention. That subtle move lines up with a research backdrop ...

Earlier this week, Insulet announced a voluntary medical device correction and recall for specific Omnipod 5 pod lots in the ...

Insulet Corp. PODD shares are down during Friday’s premarket session following the company’s announcement of a voluntary ...

A tear in the tubing may prevent users from getting full insulin doses. So far 18 people have reported serious issues related ...

An insulin pump maker is recalling certain pods that can fail to fully infuse insulin in the body. The recall comes after 18 ...

Insulet expects to incur up to $40 million in costs associated with the correction in 2026 and does not anticipate updating its previously issued guidance for the year, according to a filing with the ...

The company is recalling certain lots of its insulin patch pumps after finding a small tear in the internal tubing may cause ...

Insulet (PODD) stock slips as the company recalls some Omnipod 5 insulin pods over insulin leakage defects tied to high blood sugar risk. Read more here.

March 12 (Reuters) - Insulet has recalled specific batches of its insulin-delivery pods in the U.S. after finding a manufacturing defect that could stop diabetic users from getting their full dose of ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue ...

Insulet Corp. has identified a manufacturing issue with some of its medical devices that provide automated insulin delivery.

Expansion follows successful multi-year pilots in Massachusetts and California, and longstanding Pod takeback programs in Europe, Canada, and Australia Insulet Corporation (NASDAQ: PODD) (“Insulet” or ...